A group led by Takeda Pharmaceutical Co have completed test supplies of a blood plasma treatment for COVID-19, but pending regulator approval will likely prevent clinical trials from meeting a July start date.
Takeda-led COVID-19 plasma treatment unlikely to meet July goal of trial start
